In Germany, Kantar Health has appointed Dr Florian Eichmann as Business Unit Director, Treatment Value, responsible for its health outcomes, public health, drug surveillance, clinical research and medical device/diagnostic groups.

Kantar Health was set up by parent WPP to pool the resources of MattsonJack, TNS Healthcare, Consumer Health Sciences and Ziment.

Prior to joining, Eichmann spent thirteen years at medical research company Kendle, where he led European health outcomes, registries and observational activities, and gained experience in late-phase/post-marketing research. Before this, he worked for CRDP as Project and Laboratory Co-ordinator, Cosmetic Tests, while acting as a pharma-based medical affairs and science consultant.

Werner Guminski, CEO, Kantar Health Commercial Strategy, comments: ‘Florian combines strong scientific background with a client orientation focus and understanding of regulatory and stakeholder requirements in the clinical and market access areas. His strategic orientation and passion for development of evidence-based value messages will translate well for Kantar Health and its international clients.’

Web site: www.kantarhealth.com .

• Printer-friendly version of this article.
• Email this article to a friend.